EcoDrugPlus

Phosphodiesterase 3b

Ensembl ID : ENSOJAG00000021064
Gene Symbol: PDE3B
1 Cross references
217 Possible Orthologues:

Phosphodiesterase 4a

Ensembl ID : ENSOJAG00000021585
Gene Symbol: PDE4A
1 Cross references
201 Possible Orthologues:

Phosphodiesterase 4b

Ensembl ID : ENSOJAG00000001789
Gene Symbol: PDE4B
1 Cross references
228 Possible Orthologues:

Phosphodiesterase 4b

Ensembl ID : ENSOJAG00000005508
Gene Symbol: PDE4B
1 Cross references
224 Possible Orthologues:

Phosphodiesterase 4d

Ensembl ID : ENSOJAG00000021290
Gene Symbol: PDE4D
1 Cross references
235 Possible Orthologues:

Phosphodiesterase 5a, Cgmp-Specific, B

Ensembl ID : ENSOJAG00000022845
Gene Symbol: PDE5AB
1 Cross references
221 Possible Orthologues:

Phosphodiesterase 7a

Ensembl ID : ENSOJAG00000010274
Gene Symbol: PDE7A
1 Cross references
227 Possible Orthologues:

Phosphodiesterase 7b

Ensembl ID : ENSOJAG00000022260
Gene Symbol: PDE7B
1 Cross references
189 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 3

Ensembl ID : ENSOJAG00000000818
Gene Symbol: PIK3R3
1 Cross references
170 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 3

Ensembl ID : ENSOJAG00000010407
Gene Symbol: PIK3R3
1 Cross references
206 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSOJAG00000007977
Gene Symbol: PIK3R5
1 Cross references
200 Possible Orthologues:

Phosphoinositide-3-Kinase, Regulatory Subunit 1 (Alpha)

Ensembl ID : ENSOJAG00000019765
Gene Symbol: PIK3R1
1 Cross references
202 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).